Adaptive Biotechnologies Corporation has announced new data highlighting the growing use of its clonoSEQ® test for measurable residual disease (MRD) monitoring in hematology-oncology, showcased in 90 abstracts at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, held December 6-9, 2025. Among these, 17 abstracts demonstrate how next-generation sequencing-based MRD status is being used to guide clinical treatment decisions in blood cancer care. Notably, results from the phase II EndRAD study were presented, supporting the use of NGS MRD status before allogeneic hematopoietic cell transplantation (HCT) to guide non-total body irradiation conditioning approaches in children and young adults with B-cell acute lymphoblastic leukemia, with data showing comparable survival outcomes to standard TBI regimens.